Background: The CorMatrix (CorMatrix Cardiovascular, Roswell, Ga) biologic extracellular patch derived from porcine small intestinal mucosa provides a biologic scaffold for cellular ingrowth and eventual tissue regeneration. It has been used in a variety of applications, including cardiac and vascular repair procedures.
CorMatrix (CorMatrix Cardiovascular, Roswell, Ga) is a biologic extracellular patch derived from porcine small intestinal submucosa (SIS). It is designed to provide a biologic scaffold for cellular ingrowth and eventual tissue regeneration. CorMatrix has been successfully used in a variety of applications, including cardiac and vascular repair procedures. 1, 2 Some reports claim that the SIS material will become histologically indistinguishable from the tissue it is replacing. 3 Other reports document deficiencies in healing, resulting in significant complications. [3] [4] [5] [6] [7] The initial impetus for this report was to examine the feasibility of implanting a CorMatrix patch as part of a femoral endarterectomy procedure. Outcomes are reported with an emphasis on complications.
METHODS
Institutional Review Board approved the protocol and informed consent, and all patients gave consent. A retrospective review was conducted to evaluate results of SIS implantation as an arterioplasty patch during femoral endarterectomy procedures. Patch implantation was suspended after the seventh implant upon recognition of a pattern of early complications. These seven procedures, performed in six patients (one patient underwent staged, bilateral femoral procedures) form the basis of this report.
Consecutive SIS patch implantation was conducted at Miriam Hospital (Brown University) beginning in November 2010. The last (seventh) implant was performed in November 2011, after which no new patients received SIS implants because of recognition of patch failure. Follow-up is reported through March 2016 for all patients in the study.
Each procedure was conducted as an otherwise standard, open-surgical common femoral/proximal superficial endarterectomy. Heparin (5000-6000 units) was administered before arterial clamping. A CorMatrix four-layer SIS patch was used for arterioplasty. SIS was prepared according to the manufacturer's specifications and secured into position with running 6-0 Proline (Ethicon, Somerville, NJ) suture. Graft patency was evaluated postoperatively in an outpatient setting using duplex ultrasound imaging and supplemented with angiography when available at the time of subsequent procedures. Reporting and statistical methods are predominantly descriptive in nature. Given the relatively small number of patients, continuous data are represented as medians with interquartile ranges (IQRs).
RESULTS
Patients were a median age of 67 years (IQR, 3.6 years). Six of seven (86%) procedures were performed on male patients. The indication for surgery in each case was claudication, with severe peripheral arterial disease confirmed by angiography. There were no operative deaths. Three of seven procedures (43%) resulted in significant, early vascular complications. No complications were identified beyond the early postoperative period. All complications have been reported to the United States Food and Drug Administration (FDA). Additional details are provided in Table I . Two of seven procedures (29%) resulted in biologic extracellular matrix patch rupture, identified 11 and 19 days postoperatively. In each case, the patients had a nearly identical clinical and operative course. Patients presented to the emergency room with a large (w25-Â 15-Â 15-cm) pulsatile groin mass. Both patients underwent immediate operative exploration. After evacuation of a large hematoma, active arterial hemorrhage was identified through a frank patch rupture. A fullthickness defect, measuring 0.5 cm in diameter, was observed in the exact center of the patch. All suture lines were intact. At the time, infection was presumed the cause. Intraoperative cultures were sent and empiric antibiotics (vancomycin/piperacillin-tazobactam) started.
The SIS material was removed in its entirety and replaced with a vein patch. Several days later, all intraoperative tissue cultures were negative for infection in both patients. At the time, infection remained the suspected cause, and a full course of antibiotics with oral levofloxacin (10 days) was completed. Additional perioperative details are provided in Table II for the two patients whose patch ruptured and required a second operation. A gross specimen photograph (Fig 1) demonstrates the large, centrally located SIS patch defect. Histologic specimens (Figs 2 and 3) demonstrate that young fibroblasts have not yet produced adequate collagen. One of seven procedures (14%) resulted in pseudoaneurysm formation. The patient presented for routine, outpatient follow-up 28 days postoperatively with no complaints. The physical examination identified a golf ball-sized pulsatile mass directly underlying his femoral endarterectomy incision. The patient was thin, and the anatomy was visualized clearly. He was offered treatment but refused. This pseudoaneurysm was chronologically the third complication encountered. Immediately upon its recognition, a pattern of noninfectious patch failure was recognized, and all further implantation of SIS was suspended.
Median patient follow-up was 56 months (IQR, 6.5 months), exclusive of one patient who was lost to follow-up. No late complications were identified. The remaining (four) femoral endarterectomy SIS patches were documented as patent by duplex ultrasound imaging and angiography.
The study design did not include a control cohort. For purposes of comparison, several observations can be made. One of the study patients in whom the CorMatrix patch ruptured had also undergone previous contralateral femoral endarterectomy using Dacron (DuPont, Wilmington, Del) for patch arterioplasty without complications. During the 4-year period immediately preceding this study, the same surgeon performed 44 consecutive femoral endarterectomy procedures using a Dacron patch for arterioplasty. No ruptures, pseudoaneurysms, or reoperations were identified on follow-up. During the same interval, 112 femoral endarterectomy procedures were performed at the same hospital by a number of surgeons using a variety of patch materials. There were no known cases of rupture.
DISCUSSION
Experience with the use of SIS in vascular surgery continues to demonstrate a pattern of early complications that suggest a deficiency in patch integrity. The known process of early patch degradation needs to be matched with adequate cellular ingrowth to maintain patch strength. This appears to occur inconsistently, resulting in mechanical complications such as pseudoaneurysm formation and frank rupture.
McCready et al 3 conducted a clinical trial in which 76
patients received an SIS patch arterioplasty in conjunction with carotid endarterectomy. The study was suspended upon identification of asymptomatic pseudoaneurysm formation in seven patients (9% 4 observed an 8% (3 of 37) incidence of asymptomatic pseudoaneurysm formation, also after carotid endarterectomy. Explanted patches were negative for aerobic and anaerobic cultures. On histologic examination, a degraded patch was observed in combination with unorganized collagen and few fibroblasts. Authors conclude that "imbalances between degradation and host tissue synthesis may unpredictably affect patch integrity."
For purposes of comparison, the McCready and Weber reports provide data almost similar to oursdhuman studies using SIS for patch arterioplasty after endarterectomy, although, in the carotid position. CorMatrix received United States FDA approval for use as a carotid patch in 2011. SIS patch implantation by the Weber group was initiated after this date and therefore "on-label" in all cases. 4 Implants in the carotid position by McCready et al 3 (and femoral position in our study) preceded FDA indication. Our femoral implants were performed in the year before FDA approval for use in the carotid position. During that year, with FDA approval imminent, the carotid patch application was being heavily promoted by industry. We considered the carotid a high-risk location for an unproven product, electing to first examine SIS performance in the femoral position. Given that the patch was reported to eventually become indistinguishable from native artery, we felt that the prospect of eliminating residual foreign material could benefit a patient population with severe peripheral arterial disease that would require repeated femoral artery puncture for access in the future.
In the femoral position, two of our seven cases (29%) resulted in frank patch rupture. At the time of patch explantation, we assumed that both cases were the direct result of infection, yet all cultures proved negative. Histologic findings firmly supported absence of infection (Figs 2 and 3) . McCready and Weber also demonstrated all negative cultures in explanted specimens. Previous studies promoted SIS implants as "extremely resistant to infection" by design. 3, 8, 9 Infection proved not to be the mechanism of patch failure in our study nor does it appear to be a plausible explanation for the growing number of early patch failures reported in the literature. At the time of explantation, we observed all suture lines were intact, as have others. 3, 4 During implantation, we observed that the freshly prepared SIS material was strong, hemostatic, and handled suture well. Both of the ruptures in our patients were the result of a single, large, centrally located defect, well away from suture lines. The SIS patch, as an extracellular matrix scaffold, is purported to undergo a process of cellular ingrowth and repopulation with further claims of becoming histologically indistinguishable from normal tissue 90 days after implantation. 3 An emerging trend of reports in the literature suggests that patch "healing" does not consistently occur. In addition to cases of carotid 3, 4 and femoral endarterectomy, failures have been reported in multiple other applications. [5] [6] [7] Studies evaluating patch tensile strength at various temporal stages after implantation suggest that failure results from an early decline in patch integrity. Such findings are consistent with the time frame during which complications have been observed. Roeder et al 10 demonstrated that 10 days after implantation, the SIS graft maintains only half of its original strength. McCready et al 3 observed that a patch's mechanical integrity undergoes a "transient decrease before gradually remodeling." Early SIS graft degradation has been studied, documented, and is expected to occur. CorMatrix is a biologic material that requires remodeling. As the patch undergoes degradation, new cell ingrowth must simultaneously occur to provide a compensatory structural increase in strength. Any imbalance may result in patch weakness. Ample evidence shows patch degradation occurs early after surgical implantation. Reports from relatively "older" animal studies share remarkable similarities with recent trends observed in human applications. More than 25 years ago, after implantation of 36 SIS tube grafts in femoral and carotid positions of 18 dogs, Lantz et al 11 observed death as a direct result of graft rupture in 2 dogs, hemorrhage in 1, and aneurysm formation in Gross specimen of small intestinal submucosa (SIS) patch, explanted after rupture and significant hemorrhage, shows a relatively large defect. The defect was positioned equidistant from the lateral and medial suture lines. In this image, the lower edge is partially "rolled over" on itself due to the formalin fixation process. 13 report that explanted hemiFontan SIS patches "did not show evidence of native heart tissue ingrowth at a median of 21 months in vivo." Histologic findings of our explanted specimens are consistent with previous reports and suggested no infection and poor patch strength. Both explanted specimens were examined along a plane that included the rupture defect edge. Young fibroblasts were present but had not yet produced collagen of adequate organization and density to provide sufficient strength. The implanted SIS material had already been degraded, but the desired ingrowth of new tissue was severely limited. Sporadic ingrowth is insufficient to withstand systemic blood pressures, and rupture occurs.
Various explanations have been offered to justify early patch failure, including variability among lots and excessive preparation times. 3 Examples of such sporadic, unusual circumstances do not provide a definitive, unifying explanation. Rather, a more plausible explanation is that the required balance between SIS patch degradation and new structural ingrowth is not consistently achieved. The timing of our complications, as well as those observed by others, correspond to the early period when this imbalance is expected to occur. We appreciate the clinical potential that SIS technology may one day offer but cautiously await consistency in patch performance.
CONCLUSIONS
Use of CorMatrix patch in the femoral artery position demonstrates a high incidence of early postoperative complications, including frank patch rupture and pseudoaneurysm formation. These results are consistent with findings recently reported in the carotid artery position. The CorMatrix patch (in its current technologic state) should be used with caution, especially for applications that expose the patch to systemic blood pressures. Histologic specimen of small intestinal submucosa (SIS) patch stained with hematoxylin and eosin (original magnification Â40) shows acute and chronic inflammation with granulation tissue formation, lamellar fibrosis, myxoid stromal alteration, fibroblasts, macrophages, and focal calcification. There is no evidence of purulence, microabscesses, or macroabscesses. Minimal acute inflammatory cells are present (minimal polymorphonuclear leukocytes). The inflammation that is present is predominantly chronic inflammatory cells (lymphocytes, plasma cells, eosinophils, macrophages). Poor ingrowth is noted; granulation tissue is present but with minimal evidence of collagen formation. Collagen fibrils, which are present, tend to be single collagen fibrils with no organization, and no dense collagen is observed.
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